Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-MetS study

BackgroundAngiotensin II receptor blockers (ARBs) are recommended for treating patients with hypertension. However, comparative safety and efficacy of ARB use in elderly patients have not been well established. This study was designed to determine the efficacy of fimasartan, an ARB, in hypertensive elderly patients by measuring clinic and home blood pressures (BPs) and evaluating safety compared to nonelderly patients.MethodIn the K-MetS study, a nationwide prospective observational study of hypertensive patients on fimasartan, elderly patients (60 years and older) who were treated for 1 year with fimasartan were recruited. BP was evaluated in clinic and at home.ResultsOf the 6 399 enrolled patients, 2 363 were elderly (46.9% males, mean age 67.3 ± 5.7 years). Fimasartan reduced systolic and diastolic BP (SBP and DBP) in clinic from 144.1 ± 17.3 to 127.7 ± 12.9 mmHg and from 85.1 ± 10.4 to 76.8 ± 8.4 mmHg, respectively, (all pConclusionsFimasartan resulted in better pulse pressure reduction with similar BP reduction efficacy and safety in hypertensive elderly patients compared with nonelderly patients.背景：血管紧张素II受体拮抗剂（Angiotensin II receptor blockers, ARBs）被推荐用于高血压患者的临床治疗，但目前ARB类药物在老年人群中的比较安全性与有效性尚未得到充分证实。本研究旨在通过测量诊室与家庭血压（blood pressure, BP），对比老年与非老年高血压患者的用药安全性，评估ARB类药物菲马沙坦（fimasartan）在老年高血压患者中的治疗有效性。方法：K-MetS研究是一项针对接受菲马沙坦治疗的高血压患者的全国性前瞻性观察研究，本研究纳入其中接受菲马沙坦治疗满1年的老年患者（年龄≥60岁），并对其诊室及家庭血压进行评估。结果：共纳入6399例受试患者，其中2363例为老年患者（男性占比46.9%，平均年龄67.3±5.7岁）。菲马沙坦可使诊室收缩压（systolic blood pressure, SBP）和舒张压（diastolic blood pressure, DBP）分别从144.1±17.3 mmHg降至127.7±12.9 mmHg，以及从85.1±10.4 mmHg降至76.8±8.4 mmHg（所有p[原文此处存在截断]）。结论：与非老年高血压患者相比，老年高血压患者使用菲马沙坦可获得更优的脉压降低效果，且血压降低疗效与用药安全性与非老年患者相当。